KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Working Capital (2016 - 2023)

Historic Change in Working Capital for Gsk (GSK) over the last 15 years, with Q3 2023 value amounting to -$1.8 billion.

  • Gsk's Change in Working Capital fell 22816.43% to -$1.8 billion in Q3 2023 from the same period last year, while for Sep 2023 it was -$3.7 billion, marking a year-over-year decrease of 4362.04%. This contributed to the annual value of -$82.8 million for FY2018, which is 3233.93% up from last year.
  • As of Q3 2023, Gsk's Change in Working Capital stood at -$1.8 billion, which was down 22816.43% from -$232.2 million recorded in Q4 2022.
  • In the past 5 years, Gsk's Change in Working Capital registered a high of $1.3 billion during Q2 2022, and its lowest value of -$1.8 billion during Q3 2023.
  • For the 5-year period, Gsk's Change in Working Capital averaged around -$611.2 million, with its median value being -$685.9 million (2020).
  • In the last 5 years, Gsk's Change in Working Capital skyrocketed by 51494.1% in 2020 and then crashed by 22816.43% in 2023.
  • Over the past 5 years, Gsk's Change in Working Capital (Quarter) stood at -$1.3 billion in 2019, then skyrocketed by 50.62% to -$628.5 million in 2020, then crashed by 73.51% to -$1.1 billion in 2021, then skyrocketed by 78.7% to -$232.2 million in 2022, then plummeted by 681.04% to -$1.8 billion in 2023.
  • Its Change in Working Capital stands at -$1.8 billion for Q3 2023, versus -$232.2 million for Q4 2022 and -$552.7 million for Q3 2022.